Corbus Pharmaceuticals
CRBP
27 hedge funds and large institutions have $5.01M invested in Corbus Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
5,875% more call options, than puts
Call options by funds: $239K | Put options by funds: $4K
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.04% more ownership
Funds ownership: 16.77% → 16.81% (+0.04%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
4% less funds holding
Funds holding: 28 → 27 (-1)
14% less capital invested
Capital invested by funds: $5.8M → $5.01M (-$790K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$29.9K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$25.2K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$25.2K |
| 4 |
JP Morgan Chase
New York
|
+$10.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DWA
Dorsey Wright & Associates
Pasadena,
California
|
-$20K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$16.5K |
| 3 |
BlackRock
New York
|
-$5.4K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.34K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Comerica Bank
Dallas,
Texas
| $7 | +$7 | +1 | New |
|
|
DWA
27
Dorsey Wright & Associates
Pasadena,
California
| – | -$20K | -2,555 | Closed |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| – | -$1.15K | -147 | Closed |
|
29
Bank of America
Charlotte,
North Carolina
| – | -$8 | -1 | Closed |
|
|
NS
30
NBC Securities
Birmingham,
Alabama
| – | +$228 | +33 | New |
|
CRBP Hedge Fund Activity: Q3 2023 in Review
27 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2023, worth a combined $5.01M — down 14% from $5.8M a quarter earlier.
Fund positioning in CRBP was balanced in Q3 2023: 3 funds opened new positions, 3 closed out, 7 added to existing stakes and 4 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $29.9K. The largest seller was Dorsey Wright & Associates, exiting entirely with an estimated $20K sold.
- 27 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2023, down from 28 in Q2 2023.
- Funds reported $5.01M of Corbus Pharmaceuticals stock for Q3 2023, down 14% quarter-over-quarter.
- 3 funds opened new Corbus Pharmaceuticals positions in Q3 2023 and 3 closed out, a net change of 0 holders.
- The largest Corbus Pharmaceuticals buyer in Q3 2023 was Geode Capital Management, an estimated $29.9K added.
- The largest Corbus Pharmaceuticals seller in Q3 2023 was Dorsey Wright & Associates, an estimated $20K sold.
Based on aggregated 13F filings for Q3 2023.